• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卓越垂体肿瘤中心(PTCOE)标准的初步研究:对国际领先中心的审计结果。

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.

机构信息

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Via Olgettina 60, 20132, Milan, Italy.

Department of Endocrinology and Metabolism Disease, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.

出版信息

Pituitary. 2023 Oct;26(5):583-596. doi: 10.1007/s11102-023-01345-0. Epub 2023 Aug 28.

DOI:10.1007/s11102-023-01345-0
PMID:37640885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10539196/
Abstract

PURPOSE

The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) based on expert consensus. Aim of the study was to validate those previously proposed criteria through collection and evaluation of self-reported activity of several internationally-recognized tertiary pituitary centers, thereby transforming the qualitative 2017 definition into a validated quantitative one, which could serve as the basis for future objective PTCOE accreditation.

METHODS

An ad hoc prepared database was distributed to nine Pituitary Centers chosen by the Project Scientific Committee and comprising Centers of worldwide repute, which agreed to provide activity information derived from registries related to the years 2018-2020 and completing the database within 60 days. The database, provided by each center and composed of Excel® spreadsheets with requested specific information on leading and supporting teams, was reviewed by two blinded referees and all 9 candidate centers satisfied the overall PTCOE definition, according to referees' evaluations. To obtain objective numerical criteria, median values for each activity/parameter were considered as the preferred PTCOE definition target, whereas the low limit of the range was selected as the acceptable target for each respective parameter.

RESULTS

Three dedicated pituitary neurosurgeons are preferred, whereas one dedicated surgeon is acceptable. Moreover, 100 surgical procedures per center per year are preferred, while the results indicated that 50 surgeries per year are acceptable. Acute post-surgery complications, including mortality and readmission rates, should preferably be negligible or nonexistent, but acceptable criterion is a rate lower than 10% of patients with complications requiring readmission within 30 days after surgery. Four endocrinologists devoted to pituitary diseases are requested in a PTCOE and the total population of patients followed in a PTCOE should not be less than 850. It appears acceptable that at least one dedicated/expert in pituitary diseases is present in neuroradiology, pathology, and ophthalmology groups, whereas at least two expert radiation oncologists are needed.

CONCLUSION

This is, to our knowledge, the first study to survey and evaluate the activity of a relevant number of high-volume centers in the pituitary field. This effort, internally validated by ad hoc reviewers, allowed for transformation of previously formulated theoretical criteria for the definition of a PTCOE to precise numerical definitions based on real-life evidence. The application of a derived synopsis of criteria could be used by independent bodies for accreditation of pituitary centers as PTCOEs.

摘要

目的

垂体学会基于专家共识,为垂体肿瘤卓越中心(PTCOE)建立了概念和主要定性参数,以定义统一标准。本研究旨在通过收集和评估几个国际知名的三级垂体中心的自我报告活动来验证这些先前提出的标准,从而将 2017 年的定性定义转化为经过验证的定量定义,该定义可作为未来客观的 PTCOE 认证的基础。

方法

由项目科学委员会选择的九个垂体中心(包括世界知名的中心)提供了一个专门准备的数据库,并同意在 60 天内提供与 2018-2020 年相关的登记册相关的活动信息。每个中心提供的数据库由 Excel®电子表格组成,其中包含有关领导和支持团队的特定信息,由两名盲审员进行审查,根据评审员的评估,所有 9 个候选中心均满足整体 PTCOE 定义。为了获得客观的数值标准,中位数值被认为是首选的 PTCOE 定义目标,而范围的低值则被选为每个参数的可接受目标。

结果

每个中心首选有三位专门的垂体神经外科医生,而一位专门的外科医生是可以接受的。此外,每个中心每年优选进行 100 例手术,而结果表明每年 50 例手术是可以接受的。急性手术后并发症,包括死亡率和再入院率,最好是可以忽略不计或不存在,但可接受的标准是 30 天内因并发症需要再次入院的患者比例低于 10%。PTCOE 需要有四位专门从事垂体疾病的内分泌学家,而 PTCOE 中随访的患者总数不应少于 850 人。神经放射学、病理学和眼科学组中至少有一位专门从事垂体疾病的专家,至少有两位专家级放射肿瘤学家是可以接受的。

结论

据我们所知,这是第一项调查和评估大量垂体领域高容量中心活动的研究。这项由专门评审员内部验证的工作,使先前制定的 PTCOE 定义理论标准转化为基于实际证据的精确数值定义。衍生标准摘要的应用可由独立机构用于垂体中心的认证,作为 PTCOE。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/f86608be019f/11102_2023_1345_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/dfabed0c5b54/11102_2023_1345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/4684cf3db254/11102_2023_1345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/50bac93a8332/11102_2023_1345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/08c008a47eb3/11102_2023_1345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/5f91206fc04d/11102_2023_1345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/5effc386a5f4/11102_2023_1345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/35973d758dee/11102_2023_1345_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/67ecf6935057/11102_2023_1345_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/f86608be019f/11102_2023_1345_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/dfabed0c5b54/11102_2023_1345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/4684cf3db254/11102_2023_1345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/50bac93a8332/11102_2023_1345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/08c008a47eb3/11102_2023_1345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/5f91206fc04d/11102_2023_1345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/5effc386a5f4/11102_2023_1345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/35973d758dee/11102_2023_1345_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/67ecf6935057/11102_2023_1345_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48ae/10539196/f86608be019f/11102_2023_1345_Fig9_HTML.jpg

相似文献

1
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.卓越垂体肿瘤中心(PTCOE)标准的初步研究:对国际领先中心的审计结果。
Pituitary. 2023 Oct;26(5):583-596. doi: 10.1007/s11102-023-01345-0. Epub 2023 Aug 28.
2
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.垂体肿瘤卓越中心(PTCOE)的定义标准:垂体学会声明。
Pituitary. 2017 Oct;20(5):489-498. doi: 10.1007/s11102-017-0838-2.
3
The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective.垂体肿瘤卓越中心(PTCOE)转诊人群的最佳数量:手术视角。
Rev Endocr Metab Disord. 2020 Dec;21(4):527-536. doi: 10.1007/s11154-020-09564-7.
4
Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).垂体肿瘤卓越中心(PTCOE)肢端肥大症医学管理的护理标准。
Pituitary. 2024 Aug;27(4):381-388. doi: 10.1007/s11102-024-01397-w. Epub 2024 Jun 4.
5
Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).垂体瘤卓越中心(PTCOEs)中库欣病的医学管理路径。
Pituitary. 2025 Jan 29;28(1):23. doi: 10.1007/s11102-024-01485-x.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Pituitary Tumors Centers of Excellence.垂体瘤卓越中心。
Endocrinol Metab Clin North Am. 2020 Sep;49(3):553-564. doi: 10.1016/j.ecl.2020.05.010. Epub 2020 Jul 15.
8
Correction to: Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.对《卓越垂体瘤中心(PTCOE)定义标准:垂体协会声明》的勘误
Pituitary. 2018 Dec;21(6):663. doi: 10.1007/s11102-018-0912-4.
9
Multidisciplinary Team Care in Pituitary Tumours.垂体肿瘤的多学科团队护理
Cancers (Basel). 2024 Feb 27;16(5):950. doi: 10.3390/cancers16050950.
10
Pituitary adenoma…nomen omen?垂体腺瘤……名副其实?
Endocrine. 2021 Oct;74(1):1-4. doi: 10.1007/s12020-021-02785-z. Epub 2021 Jun 10.

引用本文的文献

1
The feedback loop in pituitary surgery.垂体手术中的反馈回路。
Pituitary. 2025 Aug 30;28(5):95. doi: 10.1007/s11102-025-01569-2.
2
Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria.评估垂体瘤的管理:与卓越垂体瘤中心标准保持一致。
Pituitary. 2025 Aug 14;28(5):91. doi: 10.1007/s11102-025-01563-8.
3
Consensus on acromegaly therapeutic outcomes: an update.肢端肥大症治疗结果共识:最新进展

本文引用的文献

1
Lack of vitamin D predicts impaired long-term immune response to COVID-19 vaccination.缺乏维生素 D 可预测对 COVID-19 疫苗接种的长期免疫反应受损。
Endocrine. 2023 Dec;82(3):536-541. doi: 10.1007/s12020-023-03481-w. Epub 2023 Aug 17.
2
Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?个体化肢端肥大症治疗:立体定向放射治疗正在改变治疗模式吗?
Front Endocrinol (Lausanne). 2022 Dec 15;13:1034576. doi: 10.3389/fendo.2022.1034576. eCollection 2022.
3
Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
Nat Rev Endocrinol. 2025 Aug 13. doi: 10.1038/s41574-025-01148-2.
4
Commentary: The updated European society of endocrinology clinical practice guideline for the management of aggressive pituitary tumors and pituitary carcinomas.评论:欧洲内分泌学会关于侵袭性垂体肿瘤和垂体癌管理的临床实践指南更新版。
Pituitary. 2025 Jul 4;28(4):84. doi: 10.1007/s11102-025-01555-8.
5
Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.垂体偶发瘤:一项垂体协会国际共识指南声明
Nat Rev Endocrinol. 2025 Jun 24. doi: 10.1038/s41574-025-01134-8.
6
Artificial intelligence in acromegaly: Why, when and how.肢端肥大症中的人工智能:为何、何时以及如何应用。
Pituitary. 2025 May 29;28(3):66. doi: 10.1007/s11102-025-01534-z.
7
The prevalence and predictors of Cushing disease recurrence: a 10-year experience of a pituitary tumor center of excellence.库欣病复发的患病率及预测因素:一家卓越垂体肿瘤中心的10年经验
Endocrine. 2025 Apr 21. doi: 10.1007/s12020-025-04234-7.
8
Headache characteristics in acromegaly: Only a secondary disorder?肢端肥大症的头痛特征:仅是一种继发性病症?
Headache. 2025 May;65(5):826-834. doi: 10.1111/head.14927. Epub 2025 Mar 13.
9
Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study.西班牙垂体腺瘤经蝶窦手术的结果:一项回顾性多中心研究。
Front Endocrinol (Lausanne). 2025 Feb 21;16:1529418. doi: 10.3389/fendo.2025.1529418. eCollection 2025.
10
Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.大泌乳素瘤患者垂体功能减退的恢复:药物治疗与手术治疗的比较。一项欧洲多中心研究的结果
J Endocrinol Invest. 2025 Mar 4. doi: 10.1007/s40618-025-02559-8.
替莫唑胺用于侵袭性垂体瘤和垂体癌的治疗
Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101713. doi: 10.1016/j.beem.2022.101713. Epub 2022 Oct 13.
4
Pituitary tumor centers of excellence for Cushing's disease.库欣病卓越垂体瘤中心
Pituitary. 2022 Oct;25(5):772-775. doi: 10.1007/s11102-022-01264-6. Epub 2022 Sep 10.
5
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.肢端肥大症诊断延迟对骨骼健康的影响:来自真实生活和长期随访经验的数据。
Pituitary. 2022 Dec;25(6):831-841. doi: 10.1007/s11102-022-01266-4. Epub 2022 Aug 3.
6
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply.奥西卓司他治疗库欣病:疗效、稳定性和持续性——作者回复
Lancet Diabetes Endocrinol. 2022 Jun;10(6):385-387. doi: 10.1016/S2213-8587(22)00135-8.
7
Spine centers of excellence: a systematic review and single-institution description of a spine center of excellence.卓越脊柱中心:卓越脊柱中心的系统评价与单机构描述
J Spine Surg. 2022 Mar;8(1):44-53. doi: 10.21037/jss-21-46.
8
Clinical Biology of the Pituitary Adenoma.垂体腺瘤的临床生物学。
Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.
9
Consensus on diagnosis and management of Cushing's disease: a guideline update.库欣病的诊断和治疗共识:指南更新。
Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20.
10
One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology.疫情一年之际——欧洲内分泌学家如何应对危机:欧洲内分泌学会的声明。
Eur J Endocrinol. 2021 Jul 5;185(2):C1-C7. doi: 10.1530/EJE-21-0397.